So­bi rene­go­ti­ates nir­se­vimab deals, to pay $81M for US roy­al­ties and axe As­traZeneca agree­ment

So­bi has an­nounced two new up­dates that it said would “stream­line” pre­vi­ous arrange­ments re­lat­ed to nir­se­vimab and give the com­pa­ny more flex­i­bil­i­ty.


Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.